Lilly and UnitedHealth Group partner on pragmatic study of neutralizing antibody bamlanivimab (LY-CoV555) for COVID-19 Read more
Y-mAbs and Takeda Announce Exclusive License and Distribution Agreement for DANYELZA (naxitamab-gqgk) and Omburtamab in Israel Read more
Tevard Biosciences and Zogenix Announce Collaboration to Advance Novel Gene Therapies for Dravet Syndrome and Other Genetic Epilepsies Read more
Roche announces FDA approval of Gavreto (pralsetinib) for people with advanced or metastatic RET-mutant and RET fusion-positive thyroid cancers Read more
Neurogene Announces EMA Grants Orphan Drug Designation for Aspartylglucosaminuria Gene Therapy Read more
First Patient Dosed in Appili Therapeutics’ Phase 3 Clinical Trial of Avigan Tablets (Favipiravir) for the Treatment of COVID-19 in the United States Read more
Merck and Artios Pharma Announce a Global Strategic Collaboration on Novel DNA Damage Response Targets in Oncology Read more
Roche receives FDA Emergency Use Authorization for new test to measure the level of SARS-CoV-2 antibodies Read more
Exelixis In-Licenses Iconic Therapeutics’ Tissue Factor-Targeting Antibody-Drug Conjugate Ahead of Planned Investigational New Drug Application Read more
Lilly announces 650,000 additional doses of neutralizing antibody bamlanivimab (LY-CoV555) purchased by U.S. government to treat COVID-19 Read more